

DAFTAR PUSTAKA

1. Smith N, Cha KB, Bichakjian C. Perioperative Consideration in Dermatologic Surgery. In: Kang S, Amagi M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, et al., editors. *Fitzpatrick's Dermatology*. 9th ed. New York: McGraw-Hill; 2019. p. 3273.
2. Deng CC, Hu YF, Zhu DH, Cheng Q, Gu JJ, Feng QL, et al. Single-cell RNA-seq reveals fibroblast heterogeneity and increased mesenchymal fibroblasts in human fibrotic skin diseases. *Nat Commun*. 2021;12(1):1–16.
3. Kendall RT, Feghali-Bostwick CA. Fibroblasts in fibrosis: Novel roles and mediators. *Front Pharmacol*. 2014;5 May(May):1–13.
4. Widaty S, Soebono H, Nilasari H, Listiawan Y, Siswati AS, Triwahyudi D, et al. Keratosis Seboroik. In: *Panduan Praktik Klinis Bagi Dokter Spesialis Kulit dan Kelamin di Indonesia*. Jakarta: PP Perdoski; 2017. p. 307–8.
5. Bahat A, Inge R, Krisanti A, Kulit D, Sakit R, Darat A, et al. Tata Laksana Laser Pada Keloid. *MDVI*. 2019;46(24):215–20.
6. Kiprono SK, Chaula BM, Masenga JE, Muchunu JW, Mavura DR, Moehrle M. Epidemiology of keloids in normally pigmented Africans and African people with albinism: Population-based cross-sectional survey. *Br J Dermatol*. 2015;173(3):852–4.
7. Kouotou EA, Nansseu JR, Omona Guissana E, Mendouga Menye CR, Akpadjan F, Tounkara TM, et al. Epidemiology and clinical features of keloids in Black Africans: a nested case-control study from Yaoundé, Cameroon. *Int J Dermatol*. 2019;58(10):1135–40.
8. Sun LM, Wang KH, Lee YCG. Keloid incidence in Asian people and its comorbidity with other fibrosis-related diseases: a nationwide population-based study. *Arch Dermatol Res*. 2014;306(9):803–8.
9. Pratiwi KD, Perdanakusuma D. Hubungan Antara Golongan Darah Dengan Timbulnya Keloid Pascaluka. 2009;05:1–8.
10. Rachmantyo B, Listiawan MY, Murtiastutik D, Sandhika W, Staf D, Fungsional M, et al. Perbandingan terapi kombinasi laser co 2 -injeksi triamsinolon dengan injeksi triamsinolon monoterapi pada keloid. *Berk Ilmu Kesehat Kulit dan Kelamin*. 2018;30(2):128.
11. Andisi RDS, Suling PL, Kapantow MG. Profil keloid di Poliklinik Kulit dan Kelamin RSUP Prof. Dr. R. D. Kandou Manado periode Januari 2011-Desember 2015. *e-CliniC*. 2016;4(2):1–6.
12. Odilia C. Profil Keloid pada Pasien RSUP Dr. M. Djamil Padang tahun 2016-2020 [skripsi]. Fakultas Kedokteran Universitas Andalas; 2021.
13. Choirunanda AF, Praharsini I. Profil Gangguan Kualitas Hidup Akibat Keloid pada Mahasiswa Fakultas Kedokteran Udayana Angkatan 2012-2014. *J Med Udayana*.

- 2019;8(8):1–5.
14. Ogawa R. Keloid and hypertrophic scars are the result of chronic inflammation in the reticular dermis. *Int J Mol Sci.* 2017;18(3):1–10.
 15. Wardani FA, Perdanakusuma DS, Indramaya DM. Profile of Working-Age Patients with Keloid and Hypertrophic Scar at Dr. Soetomo General Hospital Surabaya in 2014-2017. *JUXTA J Ilm Mhs Kedokt Univ Airlangga.* 2021;12(2):77–83.
 16. Olaitan P, Olabanji J, Oladele A, Oseni G. Symptomatology of Keloids in Africans. *Sierra Leone J Biomed Res.* 2013;5(1):29–32.
 17. Bijlard E, Kouwenberg CAE, Timman R, Hovius SER, Busschbach JJV, Mureau MAM. Burden of keloid disease: A cross-sectional health-related quality of life assessment. *Acta Derm Venereol.* 2017;97(2):225–9.
 18. Unahabhokha T, Sucontphunt A, Nimmannit U, Chanvorachote P, Yongsanguanchai N, Pongrakhananon V. Molecular signalings in keloid disease and current therapeutic approaches from natural based compounds. *Pharm Biol.* 2015;53(3):457–63.
 19. Klomprens K, Simman R. Treatment of keloids: A Meta-analysis of Intralesional Triamcinolone, Verapamil, and Their Combination. *Plast Reconstr Surg - Glob Open.* 2022;10(1):E4075.
 20. Monstrey S, Middelkoop E, Vranckx JJ, Bassetto F, Ziegler UE, Meaume S, et al. Updated Scar Management Practical Guidelines: Non-invasive and invasive measures. *J Plast Reconstr Aesthetic Surg.* 2014;67(8):1017–25.
 21. Da'i M, Triharman F. Uji Aktivitas Penangkapan Radikal DPPH (1,1-difenil-2-pikrilhidrazil) Isolat Alfa Mangostin Kulit Buah Manggis (*Garcinia mangostana* L.). *Pharmacon.* 2010;11(2):47–50.
 22. Ainul Yahya M, Hanifah Nurrosyidah I, Studi DIII Farmasi P, Anwar Medika SR, Raya By Pass Krian JK. Aktivitas antioksidan ekstrak etanol herba pegagan (*Centella asiatica* (L.) urban) dengan metode DPPH (2,2-difenil-1-pikrilhidrazil). *J Halal Prod Res.* 2020;106–12.
 23. Tharmalingam D. Uji Aktivitas Antioksidan dari Ekstrak Gambir (*Uncaria gambir* [W. hunter] roxb) dan Biji Pinang (*Areca Catechu* L.) dengan Menggunakan DPPH. Universitas Sumatera Utara; 2020.
 24. Sari II. Pengaruh Katekin Gambir (*Uncaria gambir* Roxburgh) Terhadap Proliferasi dan Migrasi Sel Fibroblasts Keloid. Universitas Andalas; 2021.
 25. Gutierrez-Orozco F, Failla ML. Biological activities and bioavailability of mangosteen xanthenes: A critical review of the current evidence. *Nutrients.* 2013;5(8):3163–83.
 26. Lee CH, Ying TH, Chiou HL, Hsieh SC, Wen SH, Chou RH, et al. Alpha-mangostin induces apoptosis through activation of reactive oxygen species and ASK1/p38 signaling pathway in cervical cancer cells. *Oncotarget.* 2017;8(29):47425–39.
 27. McFarland KL, Hahn JM, Combs KA, Supp D. Antifibrotic Effects of α -Mangostin in Fibroblasts From Keloid Lesions and Normal Skin. *Keloid Res.* 2021;1(1):1–10.
 28. Muchtaridi M, Puteri NA, Milanda T, Musfiroh I. Validation analysis methods of α -

- mangostin, γ -mangostin and gartanin mixture in Mangosteen (*Garcinia mangostana* L.) fruit rind extract from west java with HPLC. *J Appl Pharm Sci.* 2017;7(10):125–30.
29. Melia S, Novia D, Juliyarsi I, Purwati E. The characteristics of the pericarp of *Garcinia mangostana* (mangosteen) extract as natural antioxidants in rendang. *IOP Conf Ser Earth Environ Sci.* 2019;287(1):8–14.
 30. Zhang H, Tan Y ping, Zhao L, Wang L, Fu N jie, Zheng S ping, et al. Anticancer activity of dietary xanthone α -mangostin against hepatocellular carcinoma by inhibition of STAT3 signaling via stabilization of SHP1. *Cell Death Dis.* 2020;11(1).
 31. Phan TKT, Shahbazzadeh F, Kihara T. Alpha-mangostin reduces mechanical stiffness of various cells. *Hum Cell.* 2020;33(2):347–55.
 32. Ud-Din S, Bayat A. Non-animal models of wound healing in cutaneous repair: In silico, in vitro, ex vivo, and in vivo models of wounds and scars in human skin. *Wound Repair Regen.* 2017;25(2):164–76.
 33. Sharma JR, Lebeko M, Kidzeru EB, Khumalo NP, Bayat A. In Vitro and Ex Vivo Models for Functional Testing of Therapeutic Anti-scarring Drug Targets in Keloids. *Adv Wound Care.* 2019;8(12):655–70.
 34. Lebeko M, Khumalo NP, Bayat A. Multi-dimensional models for functional testing of keloid scars: In silico, in vitro, organoid, organotypic, ex vivo organ culture, and in vivo models. *Wound Repair Regen.* 2019;27(4):298–308.
 35. Gasparri F, Mariani M, Sola F, Galvani A. Quantification of the proliferation index of human dermal fibroblast cultures with the ArrayScanTM high-content screening reader. *J Biomol Screen.* 2004;9(3):232–43.
 36. Ghasemi M, Turnbull T, Sebastian S, Kempson I. The mtt assay: Utility, limitations, pitfalls, and interpretation in bulk and single-cell analysis. *Int J Mol Sci.* 2021;22(23).
 37. Gasque KCDS, Al-Ahij LP, Oliveira RC, Magalhães AC. Cell density and solvent are critical parameters affecting formazan evaluation in MTT assay. *Brazilian Arch Biol Technol.* 2014;57(3):381–5.
 38. Bobadilla AVP, Arévalo J, Sarró E, Byrne HM, Maini PK, Carraro T, et al. In vitro cell migration quantification method for scratch assays. *J R Soc Interface.* 2019;16(151).
 39. Baum J, Duffy HS. Fibroblasts and myofibroblasts: What are we talking about? *J Cardiovasc Pharmacol.* 2011;57(4):376–9.
 40. Tucci-Viegas VM, Hochman B, Frana JP, Ferreira LM. Keloid explant culture: A model for keloid fibroblasts isolation and cultivation based on the biological differences of its specific regions. *Int Wound J.* 2010;7(5):339–48.
 41. Narayana IGR, Agung IG, Praharsini A. Profil Derajat Keparahan Keloid pada Mahasiswa Fakultas Kedokteran Universitas Udayana Tahun 2015 Program Studi Pendidikan Dokter Fakultas Kedokteran Universitas Udayana 2 Divisi Kosmetik Medik Bagian / SMF Ilmu Kesehatan Kulit dan Kelamin Fakultas Kedokt. *E-Jurnal Med.* 2019;8(1):82–91.

42. Reinke JM, Sorg H. Wound repair and regeneration. *Eur Surg Res.* 2012;49(1):35–43.
43. Limandjaja GC, Niessen FB, Scheper RJ, Gibbs S. The Keloid Disorder: Heterogeneity, Histopathology, Mechanisms and Models. *Front Cell Dev Biol.* 2020;8(May):1–26.
44. Trace AP, Enos CW, Mantel A, Harvey VM. Keloids and Hypertrophic Scars: A Spectrum of Clinical Challenges. *Am J Clin Dermatol.* 2016;17(3):201–23.
45. Tiong. Challenging Diagnosis of a Rare Case of Spontaneous Keloid Scar. *J Med Cases.* 2014;(August).
46. Nicholas RS, Falvey H, Lemonas P, Damodaran G, Ghannem A, Selim F, et al. Patient-related keloid scar assessment and outcome measures. *Plast Reconstr Surg.* 2012;129(3):648–56.
47. Abdallah M, Yassin M, Saber N. Dermoscopic Features of Keloid versus Hypertrophic Scar. *Egypt J Hosp Med.* 2018;70(4):621–4.
48. Yoo MG, Kim IH. Keloids and hypertrophic scars: Characteristic vascular structures visualized by using dermoscopy. *Ann Dermatol.* 2014;26(5):603–9.
49. Limandjaja GC, van den Broek LJ, Waaijman T, Breetveld M, Monstrey S, Scheper RJ, et al. Reconstructed human keloid models show heterogeneity within keloid scars. *Arch Dermatol Res.* 2018;310(10):815–26.
50. Jiao H, Zhang T, Fan J, Xiao R. The superficial dermis may initiate keloid formation: Histological analysis of the keloid dermis at different depths. *Front Physiol.* 2017;8(NOV):1–9.
51. Wang F, Li X, Wang X, Jiang X. Efficacy of topical silicone gel in scar management: A systematic review and meta-analysis of randomised controlled trials. *Int Wound J.* 2020;17(3):765–73.
52. Blalock TW. Keloids: A Review of Etiology, Prevention, and Treatment. *J Clin Aesthet Dermatol.* 2020;13(2):33–43.
53. Ojeh N, Bharatha A, Gaur U, Forde AL. Keloids: Current and emerging therapies. *Scars, Burn Heal.* 2020;6:1–18.
54. Bijlard E. Wound Healing and Scarring. In: Hovios, editor. *Less is More in Keloid Disease.* Woensdag: Erasmus University Rotterdam; 2018. p. 168–78.
55. Nidyasari rs, akmal h, ariyanti ns. Karakterisasi Morfologi dan Anatomi Tanaman Manggis dan Kerabatnya (*Garcinia spp.*) di Taman Buah Mekarsari. *J Sumberd Hayati.* 2018;4(1):12–20.
56. Kustiari R, Purba HJ, Hermanto. An Analysis of Indonesian Mangosteen Competitiveness in the World Market (A Case Study in West Sumatera). 2012;81–107.
57. Uji T. Keanekaragaman , persebaran , dan potensi jenis-jenis garcinia di Indonesia. *Berk Penel Hayati.* 2007;12(12):129–35.
58. Irfan Z. Profil Usahatani Manggis Pada Tiga Daerah Sentra Produksi Di Sumatera Barat. In: *Seminar Nasional Hortikultura.* 2005. p. 86–104.
59. Rohman A, Rafi M, Alam G, Muchtaridi M, Windarsih A. Chemical composition and

- antioxidant studies of underutilized part of mangosteen (*Garcinia mangostana* L.) fruit. *J Appl Pharm Sci*. 2019;9(8):47–52.
60. Suttirak W, Manurakchinakorn S. In vitro antioxidant properties of mangosteen peel extract. *J Food Sci Technol*. 2014;51(12):3546–58.
 61. Kuswahyuning R, Lesmana I. Formulasi dan EValuasi Gel Ekstrak Kulti Manggis (*Garcinia mangostana* L.). *J Kefarmasian Indones*. 2021;11(2):98–108.
 62. Poerwanto R, Cahyana H, Dzajuli M, Pltono I. Optimalisasi Produksi Xanthone Manggis Sebagai Bahan Industri Fitofarmaka. Institut Pertanian Bogor; 2010.
 63. Lubis A, Darmawati E, Sutrisno. Optimasi Konsentrasi Pelilinan dan Suhu Penyimpanan Buah Manggis dengan Menggunakan Metode Respon Surface. *JTEP- Jurnal Keteknikan Pertan*. 2009;23(2):133–9.
 64. Ghasemzadeh A, Jaafar HZE, Baghdadi A, Tayebi-Meigooni A. Alpha-mangostin-rich extracts from mangosteen pericarp: Optimization of green extraction protocol and evaluation of biological activity. *Molecules*. 2018;23(8):1–16.
 65. Chen G, Li Y, Wang W, Deng L. Bioactivity and pharmacological properties of α -mangostin from the mangosteen fruit: a review. *Expert Opin Ther Pat*. 2018;28(5):415–27.
 66. Rubiyanti R, Susilawati Y, Muchtaridi. Potensi Ekonomi dan Manfaat Kandungan Alfa-Manogstin serta Gartanin dalam Kulit Buah Manggis (*Garcinia mangostana* Linn). *Univ Padjajaran*. 2014;27(4):467–8.
 67. Han SY, You BH, Kim YC, Chin YW, Choi YH. Dose-independent ADME properties and tentative identification of metabolites of α -mangostin from *Garcinia mangostana* in mice by automated microsampling and UPLC-MS/MS methods. *PLoS One*. 2015;10(7):1–16.
 68. Choi YH, Han SY, Kim YJ, Kim YM, Chin YW. Absorption, tissue distribution, tissue metabolism and safety of α -mangostin in mangosteen extract using mouse models. *Food Chem Toxicol*. 2014;66:140–6.
 69. Rukthong P, Sereesongsang N, Kulsirirat T, Boonnak N, Sathirakul K. In vitro investigation of metabolic fate of α -mangostin and gartanin via skin permeation by LC-MS/MS and in silico evaluation of the metabolites by ADMET predictorTM. *BMC Complement Med Ther*. 2020;20(1):1–10.
 70. Asasutjarit R, Meesomboon T, Adulheem P, Kittiwisut S, Sookdee P, Samosornsuk W, et al. Physicochemical properties of alpha-mangostin loaded nanomeulsions prepared by ultrasonication technique. *Heliyon*. 2019;5(9):e02465.
 71. Ashcroft KJ, Syed F, Bayat A. Site-Specific Keloid Fibroblasts Alter the Behaviour of Normal Skin and Normal Scar Fibroblasts through Paracrine Signalling. *PLoS One*. 2013;8(12).
 72. Freytag J, Wilkins-Port CE, Higgins CE, Carlson JA, Noel A, Foidart JM, et al. PAI-1 Regulates the Invasive Phenotype in Human Cutaneous Squamous Cell Carcinoma. *J Oncol*. 2009;2009:1–12.
 73. Talman V, Ruskoaho H. Cardiac fibrosis in myocardial infarction—from repair and remodeling to regeneration. *Cell Tissue Res*. 2016;365(3):563–81.

74. Li X, Yan D, Yang S, Ying H, Hui Z, Li Z. TGF-beta 1 Induced Fibroblast Proliferation in Mediated by the FGF-2/ERK Pathway. *Front Biosci.* 2012;17(4):2667–74.
75. Zhang D, Chen X, Wang Q, Wu S, Zheng Y, Liu X. Role of the MAPKs/TGF- β 1/TRAF6 signaling pathway in postoperative atrial fibrillation. *PLoS One.* 2017;12(3):1–12.
76. Papageorgis P, Stylianopoulos T. Role of TGF β in regulation of the tumor microenvironment and drug delivery (review). *Int J Oncol.* 2015;46(3):933–43.
77. Morry J, Ngamcherdtrakul W, Yantasee W. Oxidative stress in cancer and fibrosis: Opportunity for therapeutic intervention with antioxidant compounds, enzymes, and nanoparticles. *Redox Biol.* 2017;11(December 2016):240–53.
78. Sang GP, Shin H, Young KS, Lee Y, Choi EC, Park BJ, et al. The novel cytokine p43 stimulates dermal fibroblast proliferation and wound repair. *Am J Pathol.* 2005;166(2):387–98.
79. Lim CP, Phan TT, Lim IJ, Cao X. Cytokine profiling and Stat3 phosphorylation in epithelial-mesenchymal interactions between keloid keratinocytes and fibroblasts. *J Invest Dermatol* [Internet]. 2009;129(4):851–61. Available from: <http://dx.doi.org/10.1038/jid.2008.337>
80. Ghazizadeh M. Essential Role of IL-6 Signaling Pathway in Keloid Pathogenesis. *J Nippon Med Sch.* 2007;74:11–22.
81. Tschumperlin DJ. Fibroblasts and the ground they walk on. *Physiology.* 2013;28(6):380–90.
82. Ridiandries A, Tan JTM, Bursill CA. The role of chemokines in wound healing. *Int J Mol Sci.* 2018;19(10).
83. Liao WT, Yu HS, Arbiser JL, Hong CH, Govindarajan B, Chai CY, et al. Enhanced MCP-1 release by keloid CD14+ cells augments fibroblast proliferation: Role of MCP-1 and Akt pathway in keloids. *Exp Dermatol.* 2010;19(8):142–50.
84. Adenina S, Louisa M, Soetikno V, Arozal W, Wanandi SI. The effect of alpha mangostin on epithelial-mesenchymal transition on human hepatocellular carcinoma HepG2 cells surviving sorafenib via TGF- β /smad pathways. *Adv Pharm Bull.* 2020;10(4):648–55.
85. Lestari N, Louisa M, Soetikno V, Suwana AG, Ramadhan PA, Akmal T, et al. Alpha Mangostin Inhibits the Proliferation and Activation of Acetaldehyde Induced Hepatic Stellate Cells through TGF- Band ERK 1/2 Pathways. *J Toxicol.* 2018 Nov 14;2018:1–9.
86. Hu H, Tian M, Ding C, Yu S. The C/EBP homologous protein (CHOP) transcription factor functions in endoplasmic reticulum stress-induced apoptosis and microbial infection. *Front Immunol.* 2019;10(JAN):1–13.
87. Bian D, Zhang J, Wu X, Dou Y, Yang Y, Tan Q, et al. Asiatic acid isolated from centella asiatica inhibits TGF- β 1-induced collagen expression in human keloid fibroblasts via PPAR- γ activation. *Int J Biol Sci.* 2013;9(10):1032–42.

88. Mohan S, Syam S, Abdelwahab SI, Thangavel N. An anti-inflammatory molecular mechanism of action of α -mangostin, the major xanthone from the pericarp of *Garcinia mangostana*: an in silico, in vitro and in vivo approach. Vol. 9, Food and Function. 2018. 3860–3871 p.
89. Li R shi, Xu G hao, Cao J, Liu B, Xie H feng, Ishii Y, et al. Alpha-Mangostin Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Mice Partly Through Activating Adenosine 5'-Monophosphate-Activated Protein Kinase. Front Pharmacol. 2019 Nov 13;10(November).
90. Markowicz J, Uram Ł, Sobich J, Mangiardi L, Maj P, Rode W. Antitumor and anti-nematode activities of α -mangostin. Eur J Pharmacol. 2019;863(July).
91. Deng Z, Subilia M, Chin IL, Hortin N, Stevenson AW, Wood FM, et al. Keloid fibroblasts have elevated and dysfunctional mechanotransduction signaling that is independent of TGF- β . J Dermatol Sci. 2021 Oct;104(1):11–20.
92. Phan TKT, Shahbazzadeh F, Pham TTH, Kihara T. Alpha-mangostin inhibits the migration and invasion of A549 lung cancer cells. PeerJ. 2018;2018(6):1–17.

